Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00684996 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

NIH

Sponsor class

Conditions

Recurrent Renal Cell Cancer
Renal Cell Carcinoma
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions

DRUG: etaracizumab
BIOLOGICAL: bevacizumab

Sponsor

National Cancer Institute (NCI)